Polymer compositions were screened with amplitude oscillation and show synergistic effects with simulated tear fluid
Invention Summary:
Effective ophthalmic drug delivery remains a significant challenge due to the eye’s natural defense mechanisms, including blinking, tear turnover, and nasolacrimal drainage, which rapidly clear topically applied medications. While in situ gelling systems have been explored to address this issue, many rely on external triggers such as temperature or pH changes that may fail to form robust gels under physiological conditions. Therefore, there is a need for a reliable delivery system that enhances ocular residence time and can support sustained drug release.
Researchers at Rutgers have developed ocular drug delivery vehicles (ODDVs) composed of gellan gum with either hyaluronic acid or carrageenan (i.e., GG, HA, and CG in above figure). Upon contact with the eye’s natural tear film, the formulation undergoes gelation without requiring external stimuli, forming a strong, stable gel that adheres to the ocular surface, supporting prolonged residence time and the potential for reduced dosing frequency. The system is compatible with a range of therapeutics and may be used to treat conditions such as dry eye, glaucoma, bacterial conjunctivitis, and ocular hypertension.
Market Applications:
Advantages:
Intellectual Property & Development Status: Provisional application filed. Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships, contact: marketingbd@research.rutgers.edu